|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
National Comprehensive Cancer Network.
NCCN clinical practice guidelines in oncology (CN Guidelines®),
ovarian cancer. Version 5. 2020:2020, https://www2.tri-kobe.org/nccn/guideline/breast/english/ovarian.pdf.
|
|
3
|
Coleman RL, Monk BJ, Sood AK and Herzog
TJ: Latest research and treatment of advanced-stage epithelial
ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Browning L, Patel MR, Horvath EB, Tawara K
and Jorcyk CL: IL-6 and ovarian cancer: Inflammatory cytokines in
promotion of metastasis. Cancer Manag Res. 10:6685–6693. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fu S and Lin J: Blocking interleukin-6 and
interleukin-8 signaling inhibits cell viability, colony-forming
activity, and cell migration in human triple-negative breast cancer
and pancreatic cancer cells. Anticancer Res. 38:6271–6279. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Y, Yang J, Gao Y, Du Y, Bao L, Niu W
and Yao Z: Regulatory effect of e2, IL-6 and IL-8 on the growth of
epithelial ovarian cancer cells. Cell Mol Immunol. 2:365–372.
2005.PubMed/NCBI
|
|
7
|
Jayatilaka H, Tyle P, Chen JJ, Kwak M, Ju
J, Kim HJ, Lee JSH, Wu PH, Gilkes DM, Fan R and Wirtz D:
Synergistic IL-6 and IL-8 paracrine signalling pathway infers a
strategy to inhibit tumour cell migration. Nat Commun. 8:155842017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wen J, Zhao Z, Huang L, Wang L, Miao Y and
Wu J: IL-8 promotes cell migration through regulating EMT by
activating the Wnt/β-catenin pathway in ovarian cancer. J Cell Mol
Med. 24:1588–1598. 2020. View Article : Google Scholar
|
|
9
|
Yung MM, Tang HW, Cai PC, Leung TH, Ngu
SF, Chan KK, Xu D, Yang H, Ngan HY and Chan DW: GRO-α and IL-8
enhance ovarian cancer metastatic potential via the CXCR2-mediated
TAK1/NFκB signaling cascade. Theranostics. 8:1270–1285. 2018.
View Article : Google Scholar :
|
|
10
|
Zhu X, Shen H, Yin X, Long L, Chen X, Feng
F, Liu Y, Zhao P, Xu Y, Li M, et al: IL-6R/STAT3/miR-204 feedback
loop contributes to cisplatin resistance of epithelial ovarian
cancer cells. Oncotarget. 8:39154–39166. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Feng L, Qi Q, Wang P, Chen H, Chen Z, Meng
Z and Liu L: Serum levels of IL-6, IL-8, and IL-10 are indicators
of prognosis in pancreatic cancer. J Int Med Res. 46:5228–5236.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yadav A, Kumar B, Teknos TN and Kumar P:
Bazedoxifene enhances the anti-tumor effects of cisplatin and
radiation treatment by blocking IL-6 signaling in head and neck
cancer. Oncotarget. 8:66912–66924. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gennari L, Merlotti D, De Paola V, Martini
G and Nuti R: Bazedoxifene for the prevention of postmenopausal
osteoporosis. Ther Clin Risk Manag. 4:1229–1242. 2008. View Article : Google Scholar
|
|
14
|
Komm BS, Kharode YP, Bodine PV, Harris HA,
Miller CP and Lyttle CR: Bazedoxifene acetate: A selective estrogen
receptor modulator with improved selectivity. Endocrinology.
146:3999–4008. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma H, Yan D, Wang Y, Shi W, Liu T, Zhao C,
Huo S, Duan J, Tao J, Zhai M, et al: Bazedoxifene exhibits growth
suppressive activity by targeting interleukin-6/glycoprotein
130/signal transducer and activator of transcription 3 signaling in
hepatocellular carcinoma. Cancer Sci. 110:950–961. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ning Y, Labonte MJ, Zhang W, Bohanes PO,
Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO, Nagulapalli
Venkata KC, et al: The CXCR2 antagonist, SCH-527123, shows
antitumor activity and sensitizes cells to oxaliplatin in
preclinical colon cancer models. Mol Cancer Ther. 11:1353–1364.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shin HY, Yang W, Lee EJ, Han GH, Cho H,
Chay DB and Kim JH: Establishment of five immortalized human
ovarian surface epithelial cell lines via SV40 T antigen or HPV
E6/E7 expression. PLoS One. 13:e02052972018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fu S, Chen X, Lin HJ and Lin J: Inhibition
of interleukin 8/C-X-C chemokine receptor 1,/2 signaling reduces
malignant features in human pancreatic cancer cells. Int J Oncol.
53:349–357. 2018.PubMed/NCBI
|
|
20
|
Hall DM and Brooks SA: In vitro invasion
assay using Matrigel™: A reconstituted basement membrane
preparation. Methods Mol Biol. 1070:1–11. 2014. View Article : Google Scholar
|
|
21
|
Vassileva V, Moriyama EH, De Souza R,
Grant J, Allen CJ, Wilson BC and Piquette-Miller M: Efficacy
assessment of sustained intraperitoneal paclitaxel therapy in a
murine model of ovarian cancer using bioluminescent imaging. Br J
Cancer. 99:2037–2043. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Westfall SD and Skinner MK: Inhibition of
phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to
carboplatin and allows adjunct chemotherapy treatment. Mol Cancer
Ther. 4:1764–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu T, Close D, Handagama W, Marr E, Sayler
G and Ripp S: The expanding toolbox of in vivo bioluminescent
imaging. Front Oncol. 6:1502016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tian J, Chen X, Fu S, Zhang R, Pan L, Cao
Y, Wu X, Xiao H, Lin HJ, Lo HW, et al: Bazedoxifene is a novel
IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Breast Cancer Res Treat. 175:553–566. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wei J, Ma L, Lai YH, Zhang R, Li H, Li C
and Lin J: Bazedoxifene as a novel GP130 inhibitor for colon cancer
therapy. J Exp Clin Cancer Res. 38:632019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bouchard-Fortier G, Panzarella T, Rosen B,
Chapman W and Gien LT: Endometrioid carcinoma of the ovary:
Outcomes compared to serous carcinoma after 10 years of follow-up.
J Obstet Gynaecol Can. 39:34–41. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Isobe A, Sawada K, Kinose Y, Ohyagi-Hara
C, Nakatsuka E, Makino H, Ogura T, Mizuno T, Suzuki N, Morii E, et
al: Interleukin 6 receptor is an independent prognostic factor and
a potential therapeutic target of ovarian cancer. PLoS One.
10:e01180802015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X
and Xu RC: Interleukin-6 signaling regulates anchorage-independent
growth, proliferation, adhesion and invasion in human ovarian
cancer cells. Cytokine. 59:228–236. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Merritt WM, Lin YG, Spannuth WA, Fletcher
MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley
RR, et al: Effect of interleukin-8 gene silencing with
liposome-encapsulated small interfering RNA on ovarian cancer cell
growth. J Natl Cancer Inst. 100:359–372. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van Zijl F, Krupitza G and Mikulits W:
Initial steps of metastasis: Cell invasion and endothelial
transmigration. Mutat Res. 728:23–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bravo-Cordero JJ, Hodgson L and Condeelis
J: Directed cell invasion and migration during metastasis. Curr
Opin Cell Biol. 24:277–283. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Salomon-Perzyński A, Salomon-Perzyńska M,
Michalski B and Skrzypulec-Plinta V: High-grade serous ovarian
cancer: The clone wars. Arch Gynecol Obstet. 295:569–576. 2017.
View Article : Google Scholar
|
|
33
|
Mantia-Smaldone GM, Edwards RP and Vlad
AM: Targeted treatment of recurrent platinum-resistant ovarian
cancer: Current and emerging therapies. Cancer Manag Res. 3:25–38.
2011.PubMed/NCBI
|
|
34
|
Johnson DE, O'Keefe RA and Grandis JR:
Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev
Clin Oncol. 15:234–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yousefi H, Momeny M, Ghaffari SH,
Parsanejad N, Poursheikhani A, Javadikooshesh S, Zarrinrad G,
Esmaeili F, Alishahi Z, Sabourinejad Z, et al: IL-6/IL-6R pathway
is a therapeutic target in chemoresistant ovarian cancer. Tumori.
105:84–91. 2019. View Article : Google Scholar
|
|
36
|
Watson JM, Sensintaffar JL, Berek JS and
Martinez-Maza O: Constitutive production of interleukin 6 by
ovarian cancer cell lines and by primary ovarian tumor cultures.
Cancer Res. 50:6959–6965. 1990.PubMed/NCBI
|
|
37
|
Yao X, Huang J, Zhong H, Shen N, Faggioni
R, Fung M and Yao Y: Targeting interleukin-6 in inflammatory
autoimmune diseases and cancers. Pharmacol Ther. 141:125–139. 2014.
View Article : Google Scholar
|
|
38
|
Tanaka T and Kishimoto T: The biology and
medical implications of interleukin-6. Cancer Immunol Res.
2:288–294. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lane D, Matte I, Rancourt C and Piché A:
Prognostic significance of IL-6 and IL-8 ascites levels in ovarian
cancer patients. BMC Cancer. 11:2102011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ
and Li LZ: Autocrine production of interleukin-6 confers cisplatin
and paclitaxel resistance in ovarian cancer cells. Cancer Lett.
295:110–123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Todorović-Raković N and Milovanović J:
Interleukin-8 in breast cancer progression. J Interferon Cytokine
Res. 33:563–570. 2013. View Article : Google Scholar
|
|
42
|
Waugh DJ and Wilson C: The interleukin-8
pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ha H, Debnath B and Neamati N: Role of the
CXCL8-CXCR1/2 axis in cancer and inflammatory diseases.
Theranostics. 7:1543–1588. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li Y, Liu L, Yin Z, Xu H, Li S, Tao W,
Cheng H, Du L, Zhou X and Zhang B: Effect of targeted silencing of
IL-8 on in vitro migration and invasion of SKOV3 ovarian cancer
cells. Oncol Lett. 13:567–572. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Singh S, Wu S, Varney M, Singh AP and
Singh RK: CXCR1 and CXCR2 silencing modulates CXCL8-dependent
endothelial cell proliferation, migration and capillary-like
structure formation. Microvasc Res. 82:318–325. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang Y, Qu Y, Niu XL, Sun WJ, Zhang XL and
Li LZ: Autocrine production of interleukin-8 confers cisplatin and
paclitaxel resistance in ovarian cancer cells. Cytokine.
56:365–375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li
LZ and Meng XY: Interleukin-8 secretion by ovarian cancer cells
increases anchorage-independent growth, proliferation, angiogenic
potential, adhesion and invasion. Cytokine. 59:145–155. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zheng T, Ma G, Tang M, Li Z and Xu R: IL-8
secreted from M2 macrophages promoted prostate tumorigenesis via
STAT3/MALAT1 pathway. Int J Mol Sci. 20:982018. View Article : Google Scholar
|
|
49
|
Li H, Xiao H, Lin L, Jou D, Kumari V, Lin
J and Li C: Drug design targeting protein-protein interactions
(PPIs) using multiple ligand simultaneous docking (MLSD) and drug
repositioning: Discovery of raloxifene and bazedoxifene as novel
inhibitors of IL-6/GP130 interface. J Med Chem. 57:632–641. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Romero IL, Lee W, Mitra AK, Gordon IO,
Zhao Y, Leonhardt P, Penicka CV, Mui KL, Krausz TN, Greene GL and
Lengyel E: The effects of 17β-estradiol and a selective estrogen
receptor modulator, bazedoxifene, on ovarian carcinogenesis.
Gynecol Oncol. 124:134–141. 2012. View Article : Google Scholar
|
|
51
|
Singh S, Sadanandam A, Nannuru KC, Varney
ML, Mayer-Ezell R, Bond R and Singh RK: Small-molecule antagonists
for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing
tumor cell proliferation, survival, and angiogenesis. Clin Cancer
Res. 15:2380–2386. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang Y, Liu J, Jiang Q, Deng J, Xu F, Chen
X, Cheng F, Zhang Y, Yao Y, Xia Z, et al: Human adipose-derived
mesenchymal stem cell-secreted CXCL1 and CXCL8 facilitate breast
tumor growth by promoting angiogenesis. Stem Cells. 35:2060–2070.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Varney ML, Singh S, Li A, Mayer-Ezell R,
Bond R and Singh RK: Small molecule antagonists for CXCR2 and CXCR1
inhibit human colon cancer liver metastases. Cancer Lett.
300:180–188. 2011. View Article : Google Scholar
|
